The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.

@article{Liang2015TheCO,
  title={The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.},
  author={Jiaming Liang and Thibault Mespl{\`e}de and Maureen Oliveira and Kaitlin Anstett and Mark A. Wainberg},
  journal={Journal of virology},
  year={2015},
  volume={89 22},
  pages={
          11269-74
        }
}
  • Jiaming Liang, Thibault Mesplède, +2 authors Mark A. Wainberg
  • Published in Journal of virology 2015
  • Medicine, Biology
  • UNLABELLED The R263K substitution in integrase has been selected in tissue culture with dolutegravir (DTG) and has been reported for several treatment-experienced individuals receiving DTG as part of salvage therapy. The R263K substitution seems to be incompatible with the presence of common resistance mutations associated with raltegravir (RAL), a different integrase strand transfer inhibitor (INSTI). T66I is a substitution that is common in individuals who have developed resistance against a… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    4
    Twitter Mentions

    Citations

    Publications citing this paper.
    SHOWING 1-8 OF 8 CITATIONS

    Resistance to HIV integrase strand transfer inhibitors in Argentina: first interim survey

    VIEW 9 EXCERPTS
    CITES BACKGROUND
    HIGHLY INFLUENCED

    Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations

    VIEW 3 EXCERPTS
    CITES BACKGROUND
    HIGHLY INFLUENCED

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 21 REFERENCES

    Integrase Strand Transfer Inhibitors in HIV Therapy

    VIEW 6 EXCERPTS